|
|
|||
|
|||
|
|
|||
|
sublingual allergy therapy |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
sublingual allergy therapy DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide sublingual allergy therapy. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water sublingual allergy therapy. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone sublingual allergy therapy. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration sublingual allergy therapy. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide sublingual allergy therapy.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans sublingual allergy therapy. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs sublingual allergy therapy. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness sublingual allergy therapy. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges sublingual allergy therapy. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma sublingual allergy therapy. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma sublingual allergy therapy. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge sublingual allergy therapy. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma sublingual allergy therapy. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma sublingual allergy therapy. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg sublingual allergy therapy. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data sublingual allergy therapy. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% sublingual allergy therapy. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below sublingual allergy therapy. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed sublingual allergy therapy. Elderly: The apparent oral clearance of zafirlukast decreases with age sublingual allergy therapy. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients sublingual allergy therapy. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults sublingual allergy therapy. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects sublingual allergy therapy. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects sublingual allergy therapy. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| ssublingual allergy therapy suublingual allergy therapy subblingual allergy therapy subllingual allergy therapy subliingual allergy therapy sublinngual allergy therapy sublinggual allergy therapy sublinguual allergy therapy sublinguaal allergy therapy sublinguall allergy therapy sublingual allergy therapy sublingual aallergy therapy sublingual alllergy therapy sublingual alllergy therapy sublingual alleergy therapy sublingual allerrgy therapy sublingual allerggy therapy sublingual allergyy therapy sublingual allergy therapy sublingual allergy ttherapy sublingual allergy thherapy sublingual allergy theerapy sublingual allergy therrapy sublingual allergy theraapy sublingual allergy therappy sublingual allergy therapyy ublingual allergy therapy sblingual allergy therapy sulingual allergy therapy subingual allergy therapy sublngual allergy therapy subligual allergy therapy sublinual allergy therapy sublingal allergy therapy sublingul allergy therapy sublingua allergy therapy sublingualallergy therapy sublingual llergy therapy sublingual alergy therapy sublingual alergy therapy sublingual allrgy therapy sublingual allegy therapy sublingual allery therapy sublingual allerg therapy sublingual allergytherapy sublingual allergy herapy sublingual allergy terapy sublingual allergy thrapy sublingual allergy theapy sublingual allergy therpy sublingual allergy theray sublingual allergy therap s ublingual allergy therapy su blingual allergy therapy sub lingual allergy therapy subl ingual allergy therapy subli ngual allergy therapy sublin gual allergy therapy subling ual allergy therapy sublingu al allergy therapy sublingua l allergy therapy sublingual allergy therapy sublingual allergy therapy sublingual a llergy therapy sublingual al lergy therapy sublingual all ergy therapy sublingual alle rgy therapy sublingual aller gy therapy sublingual allerg y therapy sublingual allergy therapy sublingual allergy therapy sublingual allergy t herapy sublingual allergy th erapy sublingual allergy the rapy sublingual allergy ther apy sublingual allergy thera py sublingual allergy therap y sublingual allergy therapy usblingual allergy therapy sbulingual allergy therapy sulbingual allergy therapy subilngual allergy therapy sublnigual allergy therapy sublignual allergy therapy sublinugal allergy therapy sublingaul allergy therapy sublingula allergy therapy sublingua lallergy therapy sublinguala llergy therapy sublingual lalergy therapy sublingual allergy therapy sublingual alelrgy therapy sublingual allregy therapy sublingual allegry therapy sublingual alleryg therapy sublingual allerg ytherapy sublingual allergyt herapy sublingual allergy hterapy sublingual allergy tehrapy sublingual allergy threapy sublingual allergy thearpy sublingual allergy therpay sublingual allergy therayp asublingual allergy therapy thesublingual allergy therapy sublingual allergy therapy | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
